Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children?s Oncology Group (COG), the world?s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 17 years ago. The COG?s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children?s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute?s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life children with cancer and survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Statistics and Data Management Center which collaborates with COG scientific leaders to design, conduct, analyze and report the results of clinical-translational trials for the treatment of childhood cancers.
The Children?s Oncology Group (COG) is the world?s largest organization devoted exclusively to childhood and adolescent cancer research. Over 220 leading children?s hospitals, universities, and cancer centers across US, Canada and other countries participate in COG research, which is focused on developing better treatments that can improve the cure rate and outcome for all children with cancer.
|Burke, Michael J; Salzer, Wanda L; Devidas, Meenakshi et al. (2018) Replacement of cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide /etoposide during Consolidation/Delayed Intensification does not improve outcome for pediatric B-ALL: a report from the COG. Haematologica :|
|Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916|
|Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314|
|Burns, Melissa A; Liao, Zi Wei; Yamagata, Natsuko et al. (2018) Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia 32:2126-2137|
|Keller, Frank G; Castellino, Sharon M; Chen, Lu et al. (2018) Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer 124:3210-3219|
|Bolouri, Hamid; Farrar, Jason E; Triche Jr, Timothy et al. (2018) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24:103-112|
|Churchman, Michelle L; Qian, Maoxiang; Te Kronnie, Geertruy et al. (2018) Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 33:937-948.e8|
|Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034|
|Teot, Lisa A; Schneider, Michaela; Thorner, Aaron R et al. (2018) Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer 124:1973-1981|
|Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599|
Showing the most recent 10 out of 317 publications